[
  {
    "ts": null,
    "headline": "FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy",
    "summary": "Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.",
    "url": "https://finnhub.io/api/news?id=e8d36100f587ac0a78a0d5b73e2acd78e92612413060db07431b9027bb55dc24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764091680,
      "headline": "FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy",
      "id": 137606021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.",
      "url": "https://finnhub.io/api/news?id=e8d36100f587ac0a78a0d5b73e2acd78e92612413060db07431b9027bb55dc24"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial",
    "summary": "The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.",
    "url": "https://finnhub.io/api/news?id=3f8dda141eaeb677c0d049cc4fc37fbbe61b52bfb7065187b61304824f7b6576",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764082020,
      "headline": "Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial",
      "id": 137605785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.",
      "url": "https://finnhub.io/api/news?id=3f8dda141eaeb677c0d049cc4fc37fbbe61b52bfb7065187b61304824f7b6576"
    }
  },
  {
    "ts": null,
    "headline": "Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?",
    "summary": "Discover why Legend Biotech is rated a 'Strong Buy' as rising Carvykti sales drive growth.",
    "url": "https://finnhub.io/api/news?id=5a5fd84f432763684966abcc7afa84169707557fd4625c77c5b3e5f1fb0f32f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764081506,
      "headline": "Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?",
      "id": 137606292,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1924268149/image_1924268149.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why Legend Biotech is rated a 'Strong Buy' as rising Carvykti sales drive growth.",
      "url": "https://finnhub.io/api/news?id=5a5fd84f432763684966abcc7afa84169707557fd4625c77c5b3e5f1fb0f32f8"
    }
  },
  {
    "ts": null,
    "headline": "J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?",
    "summary": "J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.",
    "url": "https://finnhub.io/api/news?id=42ccd668993012cedf9961a5de78b1ccac4b109d2a8e69f66ad59467c5c6ace0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764073440,
      "headline": "J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?",
      "id": 137605788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.",
      "url": "https://finnhub.io/api/news?id=42ccd668993012cedf9961a5de78b1ccac4b109d2a8e69f66ad59467c5c6ace0"
    }
  },
  {
    "ts": null,
    "headline": "Bayer Resurrects Scrapped Blood-Thinning Drug as Breakthrough Stroke Treatment",
    "summary": "The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.",
    "url": "https://finnhub.io/api/news?id=e60775d825bc07ed9061f399c101c0bc6997bad6a58e91a84a26d48f05888360",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764070200,
      "headline": "Bayer Resurrects Scrapped Blood-Thinning Drug as Breakthrough Stroke Treatment",
      "id": 137605806,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.",
      "url": "https://finnhub.io/api/news?id=e60775d825bc07ed9061f399c101c0bc6997bad6a58e91a84a26d48f05888360"
    }
  },
  {
    "ts": null,
    "headline": "Is This the Best Value Stock to Buy While Markets Are Volatile?",
    "summary": "This big pharma stock should be even more appealing to investors amid market turbulence.",
    "url": "https://finnhub.io/api/news?id=74e47745a3166010b71072e3f4d94717858b4ed7f229fb410dc97d8e84034624",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764069840,
      "headline": "Is This the Best Value Stock to Buy While Markets Are Volatile?",
      "id": 137602793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This big pharma stock should be even more appealing to investors amid market turbulence.",
      "url": "https://finnhub.io/api/news?id=74e47745a3166010b71072e3f4d94717858b4ed7f229fb410dc97d8e84034624"
    }
  },
  {
    "ts": null,
    "headline": "Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors?",
    "summary": "Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...",
    "url": "https://finnhub.io/api/news?id=9d4a0d3eaabeca22beb0dde856fc92698c8ca792c7aff6edaa7c52f98c82ca6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764058283,
      "headline": "Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors?",
      "id": 137601631,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...",
      "url": "https://finnhub.io/api/news?id=9d4a0d3eaabeca22beb0dde856fc92698c8ca792c7aff6edaa7c52f98c82ca6a"
    }
  },
  {
    "ts": null,
    "headline": "4 takeaways from pharma’s manufacturing boom",
    "summary": "As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.",
    "url": "https://finnhub.io/api/news?id=233c1cf0383ff95697693c76296957c552c00161be33434d5f001e66289d5726",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764057600,
      "headline": "4 takeaways from pharma’s manufacturing boom",
      "id": 137605790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.",
      "url": "https://finnhub.io/api/news?id=233c1cf0383ff95697693c76296957c552c00161be33434d5f001e66289d5726"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Maintains Pfizer (PFE) Buy Recommendation",
    "summary": "Guggenheim Maintains Pfizer (PFE) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=fc0cf303b96f5f701ab8886e996064e12a7c123e89240a5aec864975be43923f",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764029163,
      "headline": "Guggenheim Maintains Pfizer (PFE) Buy Recommendation",
      "id": 137598961,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=fc0cf303b96f5f701ab8886e996064e12a7c123e89240a5aec864975be43923f"
    }
  }
]